We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

The Effect of Melatonin and Vitamin C on COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04530539
Recruitment Status : Completed
First Posted : August 28, 2020
Last Update Posted : August 17, 2022
Information provided by (Responsible Party):
Lancaster General Hospital

Brief Summary:
This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Condition or disease Intervention/treatment Phase
Covid19 SARS-CoV Infection Dietary Supplement: Vitamin C Dietary Supplement: melatonin Dietary Supplement: Placebo Other: Symptom Survey Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 122 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Supportive Care
Official Title: The Effect of Melatonin and Vitamin C on COVID-19
Actual Study Start Date : October 5, 2020
Actual Primary Completion Date : August 11, 2022
Actual Study Completion Date : August 11, 2022

Arm Intervention/treatment
Experimental: Experimental- Melatonin
Patients will receive melatonin
Dietary Supplement: melatonin
10mg melatonin, at bedtime

Other: Symptom Survey
Daily symptom survey to be completed by patient electronically

Experimental: Experimental- Vit C
Patients will receive vitamin C
Dietary Supplement: Vitamin C
1000mg Vitamin C, at bedtime
Other Name: ascorbic acid

Other: Symptom Survey
Daily symptom survey to be completed by patient electronically

Placebo Comparator: Control
Patients will receive placebo
Dietary Supplement: Placebo
Placebo at bedtime

Other: Symptom Survey
Daily symptom survey to be completed by patient electronically

Primary Outcome Measures :
  1. Symptom Severity [ Time Frame: 14 days ]
    Symptom severity will be tracked electronically

Secondary Outcome Measures :
  1. Symptom progression [ Time Frame: 14 days ]
    Determine symptom course of those with moderate or severe symptoms

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • COVID-19 positive test (outpatient testing),
  • Age >50 (chosen based greater risk for older patients to be vitamin deficient, age >65 not used so as not to be too restrictive in the inclusion criteria)
  • Experiencing symptoms for <5 days prior to enrollment
  • Able to read and write in English or Spanish
  • Able to access REDCap daily
  • Valid email address
  • Current has a Lancaster General Health primary care physician

Exclusion Criteria

  • COVID-19 test ordered pre-procedure for asymptomatic screening
  • Currently taking vitamin C supplements
  • Currently taking melatonin supplements
  • Currently hospitalized
  • Deceased
  • Currently pregnant
  • Currently incarcerated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04530539

Layout table for location information
United States, Pennsylvania
Lancaster General Health
Lancaster, Pennsylvania, United States, 17602
Sponsors and Collaborators
Lancaster General Hospital
Layout table for investigator information
Principal Investigator: Corey Fogleman Penn Medicine Lancaster General Health
Principal Investigator: Corey Fogleman, MD Physician
Layout table for additonal information
Responsible Party: Lancaster General Hospital
ClinicalTrials.gov Identifier: NCT04530539    
Other Study ID Numbers: 2020-68
First Posted: August 28, 2020    Key Record Dates
Last Update Posted: August 17, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Lancaster General Hospital:
vitamin c
Additional relevant MeSH terms:
Layout table for MeSH terms
Severe Acute Respiratory Syndrome
Pneumonia, Viral
Respiratory Tract Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Ascorbic Acid
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Central Nervous System Depressants